Evidence map›Paper›PMID 41472728›Full record

ArticleFrontiers in immunology2025

Inhibition of A2AR alleviates adenosine-mediated suppression of plasma cell differentiation.

Paola Tieppo, Hussein Shehade, Chiara Martinoli, Marjorie Mercier, David Carbonez, Nicolas Rosewick, Sophie Jung, Anais Vezzu, Boris Pirlot, Noemie Wald and 11 more

Abstract read
In one paragraph

Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Paola Tieppo *iTeos Therapeutics, Gosselies, Belgium.
Hussein Shehade *iTeos Therapeutics, Gosselies, Belgium.
Chiara Martinoli *iTeos Therapeutics, Gosselies, Belgium.
Marjorie MercieriTeos Therapeutics, Gosselies, Belgium.
David CarboneziTeos Therapeutics, Gosselies, Belgium.
Nicolas RosewickiTeos Therapeutics, Gosselies, Belgium.
Sophie JungiTeos Therapeutics, Gosselies, Belgium.
Anais VezzuiTeos Therapeutics, Gosselies, Belgium.
Boris PirlotiTeos Therapeutics, Gosselies, Belgium.
Noemie WaldiTeos Therapeutics, Gosselies, Belgium.
Stephanie MaiTeos Therapeutics, Gosselies, Belgium.
Lucas ChaibleiTeos Therapeutics, Gosselies, Belgium.
Reece MarillieriTeos Therapeutics, Gosselies, Belgium.
Francesco StrozziiTeos Therapeutics, Gosselies, Belgium.
Marie-Caroline Dieu-NosjeanSorbonne University UMRS1135, Paris, France.
Joao MarchanteiTeos Therapeutics, Gosselies, Belgium.
Margreet BrouweriTeos Therapeutics, Gosselies, Belgium.
Erica HouthuysiTeos Therapeutics, Gosselies, Belgium.
Michael DelignyiTeos Therapeutics, Gosselies, Belgium.
Yvonne McGrathiTeos Therapeutics, Gosselies, Belgium.
Maura RossettiiTeos Therapeutics, Gosselies, Belgium.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: High levels of extracellular adenosine, highly abundant in the tumor microenvironment, promote immune suppression mainly through the A2AR expressed by tumor-infiltrating immune cells. Given the importance of tumor-infiltrating B and plasma cells (PCs) in antitumor responses, we investigated the effect of A2AR on human B cells. Methods: We performed quantitative mass spectrometry imaging followed by GeoMx analysis on 10 tumor samples. Immunohistochemistry, multiplex immunofluorescence and scRNA-seq were used to assess A2AR expression on tumor and tonsillar B cells. Results: The frequency of PCs was the most negatively affected by adenosine among the immune cells present in the tumor microenvironment. Furthermore, both tonsillar and tumor-associated B cells, including germinal center (GC)-like B cells, PCs and plasma blasts, collectively referred to as antibody-secreting cells (ASCs), expressed high levels of A2AR. Triggering of A2AR inhibited B cell maturation into ASCs and immunoglobulin production Discussion: Altogether, these data demonstrate that A2AR plays a key role in adenosine-mediated inhibition of B cell maturation toward ASCs through a B cell-intrinsic mechanism, and that this effect is fully reverted by inupadenant.

Indexed as

AdenosineAdenosine A2 Receptor AntagonistsCell DifferentiationNeoplasmsPlasma CellsReceptor, Adenosine A2AB-LymphocytesFemaleHumansLymphocytes, Tumor-InfiltratingMalePhenethylaminesTumor MicroenvironmentAdenosineAdenosine A2 Receptor AntagonistsPhenethylaminesReceptor, Adenosine A2AA2ARadenosineB cellscancerplasma cells

Identifiers

PMID41472728
PMCPMC12745401

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.